A useful skincare comparator with disclosed quantity and possible ingredients. Judge the actual prescription and total care cost, not an umbrella claim about skin longevity.
- Reviewed product
- Night Renew Rx
- Listed price
- $130 / 24 g / 60-day supply
- Scope
- Skincare, not a replacement for other treatment categories
What stands out
- 24 g and 60-day supply stated
- Possible active ingredients identified
- Explicitly notes that some formulas omit tretinoin
What to weigh
- No single formula applies to every patient
- Product price may not cover every care cost
- No independent comparative trial verified in this review
A specialist comparison within a broader catalog
CoreAge Rx Review covers weight-management medicines, skincare, peptides and supplements. Agency belongs specifically in the skincare comparison. Its Night Renew prescription is an evening treatment selected after a consultation; it is not an alternative to a GLP-1 prescription, NAD+ injection or daily supplement. Keeping that scope explicit avoids turning a broad brand comparison into a misleading replacement recommendation.[source]
For a reader considering Smooth Move, the relevant Agency questions concern the actual actives, the cream base, supply quantity and clinical follow-up. The two services can describe similar appearance goals while offering different patient-specific preparations. A shared “anti-aging” label does not settle which product is appropriate.
Night Renew is an umbrella name for several formulas
Agency lists tretinoin, dexpanthenol, estriol, tranexamic acid, azelaic acid, glycerin and niacinamide as ingredients a formula may contain. It specifically notes that not every Night Renew formula contains tretinoin. This is a meaningful qualification: the product name alone does not identify the prescription.[source]
A formula containing estriol raises different assessment questions from a retinoid-only approach. Ask to see the proposed ingredients and strengths before comparing the service with CoreAge Rx. Do not add together every ingredient in the marketing menu and assume that is the medicine being dispensed.
The bottle price is not necessarily the complete care bill
The current product listing shows $130 for 24 grams, described as a 60-day supply. That is $65 per 30-day equivalent by arithmetic, not evidence of a $65 recurring monthly checkout. Confirm any additional care fees, optional products and the renewal schedule.[source]
Quantity helps make this comparison more concrete. If a competitor quote omits grams or expected supply duration, obtain that information before deciding it is cheaper. A lower bottle charge can cover a shorter period or a different formula. Likewise, a more expensive preparation is not automatically supported by stronger clinical evidence.
How we assess the longevity language
Agency frames the range around biological pathways of skin aging. Our review does not treat that language as proof that the prescribed formula changes biological age or outperforms another brand. AAD guidance on retinoids supplies useful ingredient context; FDA guidance explains why a compounded finished preparation does not carry FDA approval.[source][source]
Agency is therefore a relevant focused alternative to investigate, with unusually useful supply and ingredient details. We have not tested the cream or clinical service. The Night Renew product review examines the current formula disclosures, including the inactive ingredients that can matter to a sensitive-skin reader.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- Agency: Night Renew formula options and supply priceOfficial source; commercial claims are attributed to the provider. · Checked October 10, 2026
- American Academy of Dermatology — Retinoid or retinol?Dermatology guidance on retinoids, irritation and pregnancy · Checked October 10, 2026
- FDA — Compounding and the FDA: Questions and AnswersCompounded drugs are not FDA-approved; oversight and evidence limitations · Checked October 10, 2026